초록 ▼

Compositions which increase the bioavailability of proteinase inhibitors are disclosed. Compositions which include a pharmaceutically acceptable carrier comprising monoglycerides of medium chain-fatty acids are preferred. Preferred medium chain fatty acid glycerides include monoglycerides of saturat

Compositions which increase the bioavailability of proteinase inhibitors are disclosed. Compositions which include a pharmaceutically acceptable carrier comprising monoglycerides of medium chain-fatty acids are preferred. Preferred medium chain fatty acid glycerides include monoglycerides of saturated C.sub.6 to C.sub.12 fatty acids, preferably C.sub.8 to C.sub.10 fatty acids The pharmaceutically acceptable carrier preferably has an acid value of less than or equal to about 2.5. Preferably, the ratio of monoglycerides of medium chain fatty acid to the proteinase inhibitor is about at least 1.5.

대표청구항 ▼

[ We claim:] [1.] A unit dose pharmaceutical composition comprising:(a) an effective antiviral amount of of a compound having the formula N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3-(S)-[[N-(2-quinolylcarbo nyl)-L-asparginyl]amino]butyl]-(4aS,8aS)-isoquinline-3-carboxamide, its pharmaceuticall

[ We claim:] [1.] A unit dose pharmaceutical composition comprising:(a) an effective antiviral amount of of a compound having the formula N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3-(S)-[[N-(2-quinolylcarbo nyl)-L-asparginyl]amino]butyl]-(4aS,8aS)-isoquinline-3-carboxamide, its pharmaceutically acceptable salts or esters (including their salts); and(b) a mixture of glycerides which is about 40 to about 80% by weight of said composition; wherein said mixture of glycerides contains at least 70% monoglycerides of C.sub.8 -C.sub.10 medium chain fatty acids.